🎉 M&A multiples are live!
Check it out!

4basebio Valuation Multiples

Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Pharming, Vivoryon Therapeutics, and Julphar.

4basebio Overview

About 4basebio

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.


Founded

2019

HQ

United Kingdom of Great Britain and Northern Ireland
Employees

77

Website

4basebio.com

Financials

LTM Revenue $2.1M

LTM EBITDA -$15.1M

EV

$240M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

4basebio Financials

4basebio has a last 12-month revenue of $2.1M and a last 12-month EBITDA of -$15.1M.

In the most recent fiscal year, 4basebio achieved revenue of $0.7M and an EBITDA of -$9.5M.

4basebio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See 4basebio valuation multiples based on analyst estimates

4basebio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.7M $1.4M XXX XXX XXX
Gross Profit $0.3M $0.3M XXX XXX XXX
Gross Margin 53% 22% XXX XXX XXX
EBITDA -$9.5M -$14.1M XXX XXX XXX
EBITDA Margin -1451% -995% XXX XXX XXX
Net Profit -$4.2M -$6.6M XXX XXX XXX
Net Margin -639% -468% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

4basebio Stock Performance

As of April 15, 2025, 4basebio's stock price is GBP 12 (or $15).

4basebio has current market cap of GBP 179M (or $230M), and EV of GBP 186M (or $240M).

See 4basebio trading valuation data

4basebio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$240M $230M XXX XXX XXX XXX $-1.14

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

4basebio Valuation Multiples

As of April 15, 2025, 4basebio has market cap of $230M and EV of $240M.

4basebio's trades at 113.0x LTM EV/Revenue multiple, and -15.8x LTM EBITDA.

Analysts estimate 4basebio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for 4basebio and 10K+ public comps

4basebio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $240M XXX XXX XXX
EV/Revenue 169.2x XXX XXX XXX
EV/EBITDA -17.0x XXX XXX XXX
P/E -13.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -13.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get 4basebio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

4basebio Valuation Multiples

4basebio's NTM/LTM revenue growth is 187%

4basebio's revenue per employee for the last fiscal year averaged $8K, while opex per employee averaged $0.1M for the same period.

Over next 12 months, 4basebio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate 4basebio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for 4basebio and other 10K+ public comps

4basebio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 117% XXX XXX XXX XXX
EBITDA Margin -995% XXX XXX XXX XXX
EBITDA Growth 49% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -808% XXX XXX XXX XXX
Revenue per Employee $8K XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue 55% XXX XXX XXX XXX
G&A Expenses to Revenue 249% XXX XXX XXX XXX
R&D Expenses to Revenue 704% XXX XXX XXX XXX
Opex to Revenue 1681% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

4basebio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

4basebio M&A and Investment Activity

4basebio acquired  XXX companies to date.

Last acquisition by 4basebio was  XXXXXXXX, XXXXX XXXXX XXXXXX . 4basebio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by 4basebio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About 4basebio

When was 4basebio founded? 4basebio was founded in 2019.
Where is 4basebio headquartered? 4basebio is headquartered in United Kingdom of Great Britain and Northern Ireland.
How many employees does 4basebio have? As of today, 4basebio has 77 employees.
Who is the CEO of 4basebio? 4basebio's CEO is Dr. Heikki Lanckriet, PhD.
Is 4basebio publicy listed? Yes, 4basebio is a public company listed on LON.
What is the stock symbol of 4basebio? 4basebio trades under 4BB ticker.
When did 4basebio go public? 4basebio went public in 2021.
Who are competitors of 4basebio? Similar companies to 4basebio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of 4basebio? 4basebio's current market cap is $230M
What is the current revenue of 4basebio? 4basebio's last 12-month revenue is $2.1M.
What is the current EBITDA of 4basebio? 4basebio's last 12-month EBITDA is -$15.1M.
What is the current EV/Revenue multiple of 4basebio? Current revenue multiple of 4basebio is 113.0x.
What is the current EV/EBITDA multiple of 4basebio? Current EBITDA multiple of 4basebio is -15.8x.
What is the current revenue growth of 4basebio? 4basebio revenue growth between 2023 and 2024 was 117%.
Is 4basebio profitable? Yes, 4basebio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.